StockNews.com Downgrades West Pharmaceutical Services (NYSE:WST) to Hold

West Pharmaceutical Services (NYSE:WSTGet Rating) was downgraded by StockNews.com from a “buy” rating to a “hold” rating in a research note issued on Thursday.

WST has been the subject of a number of other research reports. William Blair reaffirmed an “outperform” rating on shares of West Pharmaceutical Services in a research note on Tuesday, February 22nd. Zacks Investment Research lowered West Pharmaceutical Services from a “buy” rating to a “hold” rating and set a $450.00 target price for the company. in a report on Saturday, January 8th.

Shares of NYSE WST opened at $325.36 on Thursday. The company has a quick ratio of 2.30, a current ratio of 2.93 and a debt-to-equity ratio of 0.09. West Pharmaceutical Services has a 12 month low of $308.36 and a 12 month high of $475.35. The company has a market cap of $24.19 billion, a price-to-earnings ratio of 37.40, a P/E/G ratio of 4.09 and a beta of 1.06. The business has a fifty day simple moving average of $385.81 and a 200-day simple moving average of $406.76.

West Pharmaceutical Services (NYSE:WSTGet Rating) last posted its quarterly earnings data on Thursday, April 28th. The medical instruments supplier reported $2.30 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.12 by $0.18. West Pharmaceutical Services had a return on equity of 31.20% and a net margin of 23.37%. The firm had revenue of $720.00 million for the quarter, compared to the consensus estimate of $720.92 million. During the same quarter in the previous year, the company earned $2.05 EPS. The business’s revenue for the quarter was up 7.4% compared to the same quarter last year. As a group, sell-side analysts expect that West Pharmaceutical Services will post 9.28 EPS for the current fiscal year.

In other West Pharmaceutical Services news, VP Quintin J. Lai sold 8,016 shares of the company’s stock in a transaction that occurred on Monday, March 14th. The shares were sold at an average price of $371.69, for a total value of $2,979,467.04. The transaction was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 0.66% of the company’s stock.

Hedge funds and other institutional investors have recently modified their holdings of the business. BlackRock Inc. increased its position in West Pharmaceutical Services by 8.9% in the 4th quarter. BlackRock Inc. now owns 8,094,288 shares of the medical instruments supplier’s stock worth $3,796,302,000 after purchasing an additional 664,275 shares during the last quarter. Norges Bank bought a new stake in shares of West Pharmaceutical Services in the 4th quarter valued at approximately $307,506,000. Invesco Ltd. increased its holdings in West Pharmaceutical Services by 14.0% in the third quarter. Invesco Ltd. now owns 1,260,099 shares of the medical instruments supplier’s stock worth $534,963,000 after buying an additional 154,534 shares during the last quarter. Arrowstreet Capital Limited Partnership raised its position in West Pharmaceutical Services by 42.3% during the third quarter. Arrowstreet Capital Limited Partnership now owns 515,148 shares of the medical instruments supplier’s stock valued at $218,701,000 after acquiring an additional 153,180 shares in the last quarter. Finally, Brown Advisory Inc. lifted its stake in West Pharmaceutical Services by 8.5% in the fourth quarter. Brown Advisory Inc. now owns 1,338,591 shares of the medical instruments supplier’s stock valued at $627,811,000 after acquiring an additional 105,397 shares during the last quarter. Hedge funds and other institutional investors own 91.24% of the company’s stock.

West Pharmaceutical Services Company Profile (Get Rating)

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.

Featured Articles

Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.